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Edited by Veli-Pekka LehtoAbstract Angiogenesis is important for normal growth and
wound healing processes. An imbalance of the growth factors in-
volved in this process, however, causes the acceleration of several
diseases including malignant, ocular, and inﬂammatory diseases.
Inhibiting angiogenesis through interfering with its pathway is a
promising methodology to hinder the progression of these dis-
eases. Herein, we studied the anti-angiogenic eﬀects of various
carbon materials such as graphite, multiwalled carbon nanotubes
and fullerenes in vascular endothelial growth factor (VEGF) and
basic ﬁbroblast growth factor (FGF2)-induced angiogenesis eval-
uated in the chick chorioallantoic membrane (CAM) model. All
the carbon materials tested showed substantial anti-angiogenic
activity against either FGF2- or VEGF-induced angiogenesis in
the CAM model. Those carbon materials did not have any signif-
icant eﬀects on basal angiogenesis in the absence of the added
growth factors.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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CAM assay1. Introduction
Angiogenesis (the formation of new blood vessels) is an
essential event for normal growth processes including embry-
onic development, wound healing and the menstrual cycle
[1]. Various growth factors such as vascular endothelial growth
factor (VEGF), ﬁbroblast growth factors (acidic and basic
FGFs) and angiopoietin are involved in neovascularization.
Growth factors such as basic FGF (or FGF2) and VEGF in-
duce endothelial cells to secrete proteases and plasminogen
activators that degrade the vessel basement membrane, leading
to cell invasion into the surrounding matrix and the formation
of new vessels. Thus, VEGF and FGF2 constitute the most
important growth factors that induce angiogenesis [2]. An*Corresponding author. Fax: +1 518 276 3405.
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doi:10.1016/j.febslet.2007.02.022imbalance in the levels of these factors will cause many serious
diseases including malignant cell growth.
Angiogenesis is required for cancer tumor survival and
metastasis [1,3,4]. Inhibiting angiogenesis can both eliminate
the blood supply to the primary cancer cells and prevent can-
cer metastasis [5]. The current strategy of inhibiting angiogen-
esis relies mainly on inhibiting the activities of the growth
factors and/or interfering in the angiogenesis pathways. Vari-
ous angiogenesis inhibitors such as angiostatin, endostatin
and interferons have been found to eﬀectively arrest the cancer
metastasis [5–7]. There is still active research being carried out
to ﬁnd less expensive, more potent, easily administrable and
more common inhibitors.
Nanomaterials such as liposomes, polymeric nanoparticles,
metallic and non-metallic nanoparticles, carbon nanotubes,
nanowires, viral nanoparticles and hybrids, quantum dots
and dendrimers are currently being proposed, with appropriate
surface modiﬁcations, as tools for drug delivery and imaging
and in cancer treatment and diagnosis [8,9]. The numerous
potential applications of nanomaterials in cancer research diag-
nosis and treatment have given rise to the new ﬁeld of ‘‘nano-
oncology’’. Carbon-based nanomaterials such as carbon nano-
tubes, fullerenes and carbon nanoﬁbers are preferred over other
nanomaterials owing to their high aspect ratio, mechanical
strength, ease of chemical/physical conjugation with small
and macromolecules, high surface area, easy manufacturability
and light weight. Biocompatibility, blood compatibility, bioc-
learance and toxicology are some of the many issues that need
to be addressed when proposing the use of nanomaterials in
biomedical applications [10]. Surface modiﬁed hydrophilic car-
bon nanotubes were recently reported to have excellent bioclea-
rance through the kidney when administered in vivo in mice
[11]. In addition, our laboratory has recently demonstrated that
multiwalled carbon nanotubes (MWNTs), modiﬁed with hepa-
rin, show excellent blood compatibility [12]. These studies sug-
gest the possibility of using carbon nanotubes (CNTs) in
various in vivo biomedical applications including the treatment
of cancer, with appropriate surface modiﬁcations [13].
Here we report the anti-angiogenic eﬃcacy of pristine
(unmodiﬁed) MWNTs, C60 fullerenes and graphite by using
VEGF/FGF2 induced angiogenesis in chick chorioallantoic
membrane (CAM). All three carbon materials showed signiﬁ-
cant anti-angiogenic activity, with eﬃcacy diﬀering with re-
spect to the promoters (VEGF/FGF2).ation of European Biochemical Societies.
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2.1. Materials
High purity MWNTs and fullerenes were purchased from Carbon
Nanotechnologies Inc., and used without any puriﬁcation. Human re-
combinant VEGF and human recombinant FGF2 were purchased
from R&D Systems (Minneapolis, MN). Ten-day-old chick embryos
were purchased from SPAFAS (Preston, CT). Sterile ﬁlter paper disks
were purchased from Whatman International (Florham Park, NJ).
2.2. Methods
2.2.1. Physical binding studies. MWNTs, fullerenes and graphite
were evaluated for any physical binding that might occur with the
growth factors. MWNTs, fullerenes and graphite (100 lg) were incu-
bated with VEGF (2 lg/ml) or FGF2 (1.5 lg/ml) in phosphate buﬀered
saline (PBS) (1 ml) at 37 C for 24 h. After incubation, the solution was
ﬁltered from the carbon-based materials and tested for VEGF/FGF2
by using UV at 280 nm. A standard curve of growth factor concentra-
tion versus UV absorbance was used for calibration.
2.2.2. CAM assay. Angiogenesis was examined by CAM model
that has been described in detail previously [14–16]. The 10-day-old
chick embryos were incubated at 37 C with 55% relative humidity.
A small hole was made in the shell concealing the air sac by using a
hypodermic needle. A second hole was made on the broad side of
the egg, directly over an avascular portion of the embryonic membrane
that was identiﬁed by candling. By applying negative pressure at the
ﬁrst hole, a false air sac was created beneath the second hole, causing
the CAM to separate from the shell. A window 2.0 cm2 was cut in the
shell over the dropped CAM with a small-crafts grinding wheel (Dre-
mel, Emerson Electric Co.), allowing direct access to the underlying
CAM. FGF2 (1.5 lg/mL) was used as a standard pro-angiogenic agent
to induce new blood vessel branches on the CAM of 10-day-old em-
bryos. Sterile ﬁlter paper disks were pretreated with 3 mg/mL cortisone
acetate and air dried under sterile conditions. PBS (control), FGF2 or
VEGF and the MWNTs, fullerenes or graphite were then applied to
the cortisone acetate pretreated disks (1.0 cm, diameter) and dried.
The disks were suspended in PBS, and placed on growing CAMs.
2.2.3. Microscopic analysis of CAM sections. After incubation
with 55% relative humidity at 37 C for 3 days, the CAM tissue di-
rectly below the ﬁlter disk was cut oﬀ and washed three times with
PBS. The washed tissues were then placed in 35-mm Petridishes,
and examined under a Karl Zeiss SV6 stereomicroscope (Thornwood,
NY) at 50-fold magniﬁcation. Digital images of CAM tissues wereFig. 1. Representative microscopic images of (a) PBS control; (b)collected using a 3-CCD color video camera system from Toshiba
America (New York, NY), and analyzed with Image-Pro software
from Media Cybernetics (Silver Spring, MD). The number of vessel
branch points contained in a circular region equal to the area of each
CAM preparation (1.5 cm2), and ﬁndings from 7 to 8 CAM prepara-
tions were analyzed for each treatment condition. The resulting angi-
ogenesis index is the mean ± S.E.M. of new branch points in each set
of samples. The % inhibition was calculated using the following equa-
tion:
%Inhibition ¼ 100 ½ðTest agent plus VEGF or FGF2Þ
 PBSðcontrolÞ=½ðVEGF or FGF2Þ
 PBSðcontrolÞ  100
** Mean % inhibition was then calculated based on the diﬀerent (n) car-
ried out
2.2.4. Statistical analysis. Statistical analyses of blood vessel
branching patterns were performed by one-way analysis of variance
(ANOVA) comparing experimental data with control groups.3. Results
The anti-angiogenic activities were evaluated by using either
VEGF or FGF2 stimulated angiogenesis in the CAM model.
This assay is a well established, fast and simple, real time
in vivo assay, and is suitable for the evaluation of potential
angiogenesis inhibitors or stimulators in a living organism
[17]. The carbon materials used did not have any signiﬁcant ef-
fects on basal angiogenesis as compared to control group
(Fig. 1 and Table 1). In VEGF induced angiogenesis, new
blood vessels were stimulated by the addition of VEGF as
shown in the representative illustration in Fig. 2b. Increased
neovascularization is observed in comparison to CAM treated
with PBS buﬀer alone – Fig. 2a. When CAM was treated with
MWNTs, fullerenes or graphite, angiogenesis was inhibited to
a signiﬁcant extent (Table 2). Graphite at 100 lg showed the
strongest inhibition of angiogenesis (64.3 ± 7.5%), followed
by fullerenes (49.6 ± 7.6%) and MWNTs (37.1 ± 21.1%).graphite; (c) fullerene; (d) MWNTs – treated CAM models.
Table 1
Eﬀect of MWNTs, fullerenes and graphite on basal angiogenesis in the
CAM model
Treatment Mean branch points ± S.E.M.
PBS (control) 71.0 ± 5
FGF2 (1 lg/ml) 155.5 ± 8**
VEGF (2 lg/ml) 161.2 ± 11**
MWNTs (100 lg) 81.3 ± 8
Fullerene (100 lg) 72.0 ± 5
Graphite (100 lg) 75.3 ± 5
Data represent mean + S.E.M., n = 7 per group, P < 0.001 as com-
pared to control.
Table 2
Percentage inhibition of VEGF/FGF2 induced angiogenesis up on
treating with MWNTs, fullerenes and graphite
Treatment groups Branch points ±
S.E.M.
%Inhibition ±
S.E.M.
PBS 64.5 ± 8.6
VEGF (2 lg/ml) 163.6 ± 12.6
VEGF + MWNTs (100 lg) 129.8 ± 21.9 37.1 ± 21.1*
VEGF + fullerenes (100 lg) 116.8 ± 7.9 49.6 ± 7.6**
VEGF + graphite (100 lg) 101.5 ± 7.8 64.3 ± 7.5**
FGF2 (1.5 lg/ml) 168.3 ± 9.3
FGF2 + MWNTs (100 lg) 130.8 ± 16.4 36.1 ± 15.8*
FGF2 + fullerenes (100 lg) 147.3 ± 21.7 20.2 ± 12.9*
FGF2 + graphite (100 lg) 130.3 ± 12.3 36.6 ± 11.8*
FGF2 + MWNTs (1 mg) 91.5 ± 8.2 76.4 ± 9.6**
Data represents mean ± S.E.M., n = 8 per group.
*P < 0.05.
**P < 0.01.
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control in Fig. 3a. Graphite and MWNTs showed approxi-
mately equal levels of inhibition (36%) of FGF2 induced
angiogenesis, followed by fullerenes (20%). A dose response
relationship in the FGF2 system is clearly illustrated by an in-
crease from 36 ± 15.8% inhibition to 76.4 ± 9.6% inhibition
with 100 lg versus 1 mg of MWNTs, respectively. Binding
studies, performed by adding growth factors to carbon-based
materials in PBS, removing these materials by ﬁltration and
measuring residual growth factors, showed that the growth
factors were not physically adsorbed to the carbon materials.4. Discussion
To our knowledge, this is the ﬁrst report of the anti-angio-
genesis activity associated with carbon materials such as
MWNTs, fullerenes and graphite. Next, we performed adsorp-
tion experiments to assess whether VEGF or FGF2 bound to
these carbon materials physically. Neither VEGF nor FGF2
adsorbed on to any of the carbon materials studied. Gold
nanoparticles reportedly inhibit VEGF165-induced prolifera-
tion of HUVEC cells by binding the sulfur/amines present inFig. 2. Representative microscopic images of (a) PBS control; (b) VEGF; (c)
CAM models.the heparin binding domains of VEGF165 [18]. While it is un-
clear how carbon inhibits angiogenesis, it is not the result of
the physical adsorption of the growth factors on carbon mate-
rials. Carbon materials might block the binding of VEGF and
FGF2 with their receptors interfering with signal transduction.
No toxicity of these materials was observed in the fertilized
eggs used in these experiments. Upon the termination of the
study and after 3 days of exposure to the carbon materials,
the embryos were examined and compared in all groups. There
was no eﬀect on the survival of the embryos or any apparent
adverse eﬀects based on gross examination. More detailed
mechanistic studies are currently underway in our laboratories.
MWNTs can also be loaded with anti-cancer agents (small or
macromolecular drug) through either by chemical or physical
attachment methods. The intrinsic anti-angiogenic activity of
MWNTs might aﬀord a synergistic cancer treating strategy.
Carbon based nanomaterials including nanotubes and
fullerenes are widely proposed for various applications ofVEGF – MWNTs; (d) VEGF – graphite; (e) VEGF – fullerene treated
Fig. 3. Representative microscopic images of (a) PBS control; (b) FGF2; (c) FGF2 – MWNTs (100 lg); (d) FGF2 – graphite; (e) FGF2 – fullerene;
(f) FGF2 – MWNTs (1 mg) treated CAM models.
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ated the anti-angiogenic activity of pristine MWNTs, fulle-
renes and graphite. In both VEGF and FGF2 induced
angiogenesis in the CAM model, carbon materials showed sig-
niﬁcant inhibition of angiogenesis. To the extent of our knowl-
edge, this is the ﬁrst observation of the anti-angiogenic activity
of carbon materials. There is a relatively greater potency in
inhibiting VEGF versus FGF2 in the CAM model by the var-
ious carbon materials.References
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